Ziconotide: A new option for refractory pain

Eric Prommer

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Ziconotide has been introduced as a new non-opioid treatment for chronic pain. Structurally, it is a peptide, the synthetic analog of the omega-conotoxin, derived from the marine snail, Conus magus. N-type voltage-sensitive calcium channels play a role in the transmission of nociceptive stimuli and also are involved in the release of neurotransmitters important in pain transmission. Ziconotide's therapeutic benefit derives from its potent and selective blockade of neuronal-type voltage-sensitive calcium channels. Blockade of the channels results in suppression of abnormal ectopic discharges from the injury site or the dorsal root ganglia, possibly resulting in decreased neuroplasticity, and decreased synaptic transmission that leads to the generation of chronic pain syndromes. The advantage of ziconotide is that tolerance does not occur, while disadvantages associated with ziconotide are the need for intrathecal administration and significant neurotoxicites associated with its use. When tested in clinical trials, ziconotide has been shown to have synergistic or additive value to the effect of morphine. Ziconotide, formerly known also as SNX-111, represents a new class of agents, the N-type calcium channel blockers. These may represent another option for patients with refractory pain and refractory pain syndromes.

Original languageEnglish (US)
Pages (from-to)369-378
Number of pages10
JournalDrugs of Today
Volume42
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Intractable Pain
Calcium Channels
Chronic Pain
N-Type Calcium Channels
omega-Conotoxins
Conus Snail
Neuronal Plasticity
Calcium Channel Blockers
Spinal Ganglia
ziconotide
Synaptic Transmission
Morphine
Neurotransmitter Agents
Clinical Trials
Pain
Peptides
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Ziconotide : A new option for refractory pain. / Prommer, Eric.

In: Drugs of Today, Vol. 42, No. 6, 06.2006, p. 369-378.

Research output: Contribution to journalArticle

Prommer, Eric. / Ziconotide : A new option for refractory pain. In: Drugs of Today. 2006 ; Vol. 42, No. 6. pp. 369-378.
@article{c87c843866f24c768c313aa43c616619,
title = "Ziconotide: A new option for refractory pain",
abstract = "Ziconotide has been introduced as a new non-opioid treatment for chronic pain. Structurally, it is a peptide, the synthetic analog of the omega-conotoxin, derived from the marine snail, Conus magus. N-type voltage-sensitive calcium channels play a role in the transmission of nociceptive stimuli and also are involved in the release of neurotransmitters important in pain transmission. Ziconotide's therapeutic benefit derives from its potent and selective blockade of neuronal-type voltage-sensitive calcium channels. Blockade of the channels results in suppression of abnormal ectopic discharges from the injury site or the dorsal root ganglia, possibly resulting in decreased neuroplasticity, and decreased synaptic transmission that leads to the generation of chronic pain syndromes. The advantage of ziconotide is that tolerance does not occur, while disadvantages associated with ziconotide are the need for intrathecal administration and significant neurotoxicites associated with its use. When tested in clinical trials, ziconotide has been shown to have synergistic or additive value to the effect of morphine. Ziconotide, formerly known also as SNX-111, represents a new class of agents, the N-type calcium channel blockers. These may represent another option for patients with refractory pain and refractory pain syndromes.",
author = "Eric Prommer",
year = "2006",
month = "6",
doi = "10.1358/dot.2006.42.6.973534",
language = "English (US)",
volume = "42",
pages = "369--378",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "6",

}

TY - JOUR

T1 - Ziconotide

T2 - A new option for refractory pain

AU - Prommer, Eric

PY - 2006/6

Y1 - 2006/6

N2 - Ziconotide has been introduced as a new non-opioid treatment for chronic pain. Structurally, it is a peptide, the synthetic analog of the omega-conotoxin, derived from the marine snail, Conus magus. N-type voltage-sensitive calcium channels play a role in the transmission of nociceptive stimuli and also are involved in the release of neurotransmitters important in pain transmission. Ziconotide's therapeutic benefit derives from its potent and selective blockade of neuronal-type voltage-sensitive calcium channels. Blockade of the channels results in suppression of abnormal ectopic discharges from the injury site or the dorsal root ganglia, possibly resulting in decreased neuroplasticity, and decreased synaptic transmission that leads to the generation of chronic pain syndromes. The advantage of ziconotide is that tolerance does not occur, while disadvantages associated with ziconotide are the need for intrathecal administration and significant neurotoxicites associated with its use. When tested in clinical trials, ziconotide has been shown to have synergistic or additive value to the effect of morphine. Ziconotide, formerly known also as SNX-111, represents a new class of agents, the N-type calcium channel blockers. These may represent another option for patients with refractory pain and refractory pain syndromes.

AB - Ziconotide has been introduced as a new non-opioid treatment for chronic pain. Structurally, it is a peptide, the synthetic analog of the omega-conotoxin, derived from the marine snail, Conus magus. N-type voltage-sensitive calcium channels play a role in the transmission of nociceptive stimuli and also are involved in the release of neurotransmitters important in pain transmission. Ziconotide's therapeutic benefit derives from its potent and selective blockade of neuronal-type voltage-sensitive calcium channels. Blockade of the channels results in suppression of abnormal ectopic discharges from the injury site or the dorsal root ganglia, possibly resulting in decreased neuroplasticity, and decreased synaptic transmission that leads to the generation of chronic pain syndromes. The advantage of ziconotide is that tolerance does not occur, while disadvantages associated with ziconotide are the need for intrathecal administration and significant neurotoxicites associated with its use. When tested in clinical trials, ziconotide has been shown to have synergistic or additive value to the effect of morphine. Ziconotide, formerly known also as SNX-111, represents a new class of agents, the N-type calcium channel blockers. These may represent another option for patients with refractory pain and refractory pain syndromes.

UR - http://www.scopus.com/inward/record.url?scp=33746261240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746261240&partnerID=8YFLogxK

U2 - 10.1358/dot.2006.42.6.973534

DO - 10.1358/dot.2006.42.6.973534

M3 - Article

C2 - 16845440

AN - SCOPUS:33746261240

VL - 42

SP - 369

EP - 378

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 6

ER -